These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 12900284

  • 1. Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid for radiolabeling proteins.
    Chappell LL, Ma D, Milenic DE, Garmestani K, Venditto V, Beitzel MP, Brechbiel MW.
    Nucl Med Biol; 2003 Aug; 30(6):581-95. PubMed ID: 12900284
    [Abstract] [Full Text] [Related]

  • 2. Preparation and biological evaluation of 111In-, 177Lu- and 90Y-labeled DOTA analogues conjugated to B72.3.
    Mohsin H, Fitzsimmons J, Shelton T, Hoffman TJ, Cutler CS, Lewis MR, Athey PS, Gulyas G, Kiefer GE, Frank RK, Simon J, Lever SZ, Jurisson SS.
    Nucl Med Biol; 2007 Jul; 34(5):493-502. PubMed ID: 17591549
    [Abstract] [Full Text] [Related]

  • 3. In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications.
    Milenic DE, Garmestani K, Chappell LL, Dadachova E, Yordanov A, Ma D, Schlom J, Brechbiel MW.
    Nucl Med Biol; 2002 May; 29(4):431-42. PubMed ID: 12031878
    [Abstract] [Full Text] [Related]

  • 4. Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands.
    Hens M, Vaidyanathan G, Welsh P, Zalutsky MR.
    Nucl Med Biol; 2009 Feb; 36(2):117-28. PubMed ID: 19217523
    [Abstract] [Full Text] [Related]

  • 5. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL, Govindan SV, Sharkey RM, Fisher DR, Goldenberg DM.
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of 177Lu-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties.
    Knogler K, Grünberg J, Novak-Hofer I, Zimmermann K, Schubiger PA.
    Nucl Med Biol; 2006 Oct; 33(7):883-9. PubMed ID: 17045168
    [Abstract] [Full Text] [Related]

  • 7. Preparation of 177 Lu-labeled Nimotuzumab for radioimmunotherapy of EGFR-positive cancers: Comparison of DOTA and CHX-A″-DTPA as bifunctional chelators.
    Pandey U, Kameswaran M, Gamre N, Dash A.
    J Labelled Comp Radiopharm; 2019 Apr; 62(4):158-165. PubMed ID: 30663095
    [Abstract] [Full Text] [Related]

  • 8. Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
    Yordanov AT, Hens M, Pegram C, Bigner DD, Zalutsky MR.
    Nucl Med Biol; 2007 Feb; 34(2):173-83. PubMed ID: 17307125
    [Abstract] [Full Text] [Related]

  • 9. Improved synthesis of the bifunctional chelating agent 1,4,7,10-tetraaza-N-(1-carboxy-3-(4-nitrophenyl)propyl)-N',N'',N'''-tri s(acetic acid)cyclododecane (PA-DOTA).
    Chappell LL, Rogers BE, Khazaeli MB, Mayo MS, Buchsbaum DJ, Brechbiel MW.
    Bioorg Med Chem; 1999 Nov; 7(11):2313-20. PubMed ID: 10632041
    [Abstract] [Full Text] [Related]

  • 10. H(2)azapa: a versatile acyclic multifunctional chelator for (67)Ga, (64)Cu, (111)In, and (177)Lu.
    Bailey GA, Price EW, Zeglis BM, Ferreira CL, Boros E, Lacasse MJ, Patrick BO, Lewis JS, Adam MJ, Orvig C.
    Inorg Chem; 2012 Nov 19; 51(22):12575-89. PubMed ID: 23106422
    [Abstract] [Full Text] [Related]

  • 11. A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates.
    Lewis MR, Raubitschek A, Shively JE.
    Bioconjug Chem; 1994 Nov 19; 5(6):565-76. PubMed ID: 7873659
    [Abstract] [Full Text] [Related]

  • 12. Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
    Hens M, Vaidyanathan G, Zhao XG, Bigner DD, Zalutsky MR.
    Nucl Med Biol; 2010 Oct 19; 37(7):741-50. PubMed ID: 20870149
    [Abstract] [Full Text] [Related]

  • 13. In vitro and in vivo evaluation of novel ligands for radioimmunotherapy.
    Chong HS, Milenic DE, Garmestani K, Brady ED, Arora H, Pfiester C, Brechbiel MW.
    Nucl Med Biol; 2006 May 19; 33(4):459-67. PubMed ID: 16720237
    [Abstract] [Full Text] [Related]

  • 14. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
    Stein R, Govindan SV, Chen S, Reed L, Richel H, Griffiths GL, Hansen HJ, Goldenberg DM.
    J Nucl Med; 2001 Jun 19; 42(6):967-74. PubMed ID: 11390564
    [Abstract] [Full Text] [Related]

  • 15. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
    Perk LR, Visser GW, Vosjan MJ, Stigter-van Walsum M, Tijink BM, Leemans CR, van Dongen GA.
    J Nucl Med; 2005 Nov 19; 46(11):1898-906. PubMed ID: 16269605
    [Abstract] [Full Text] [Related]

  • 16. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to 111In and 177Lu-An EGFR-Targeted Theranostic for Pancreatic Cancer.
    Aghevlian S, Lu Y, Winnik MA, Hedley DW, Reilly RM.
    Mol Pharm; 2018 Mar 05; 15(3):1150-1159. PubMed ID: 29314858
    [Abstract] [Full Text] [Related]

  • 17. AAZTA5-squaramide ester competing with DOTA-, DTPA- and CHX-A″-DTPA-analogues: Promising tool for 177Lu-labeling of monoclonal antibodies under mild conditions.
    Klasen B, Moon ES, Rösch F.
    Nucl Med Biol; 2021 Mar 05; 96-97():80-93. PubMed ID: 33839678
    [Abstract] [Full Text] [Related]

  • 18. Comparative Evaluation of Using NOTA and DOTA Derivatives as Bifunctional Chelating Agents in the Preparation of 68Ga-Labeled Porphyrin: Impact on Pharmacokinetics and Tumor Uptake in a Mouse Model.
    Guleria M, Das T, Amirdhanayagam J, Sarma HD, Dash A.
    Cancer Biother Radiopharm; 2018 Feb 05; 33(1):8-16. PubMed ID: 29373046
    [Abstract] [Full Text] [Related]

  • 19. Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates.
    Ghosh SC, Pinkston KL, Robinson H, Harvey BR, Wilganowski N, Gore K, Sevick-Muraca EM, Azhdarinia A.
    Nucl Med Biol; 2015 Feb 05; 42(2):177-83. PubMed ID: 25457653
    [Abstract] [Full Text] [Related]

  • 20. DOTA-functionalized polylysine: a high number of DOTA chelates positively influences the biodistribution of enzymatic conjugated anti-tumor antibody chCE7agl.
    Grünberg J, Jeger S, Sarko D, Dennler P, Zimmermann K, Mier W, Schibli R.
    PLoS One; 2013 Feb 05; 8(4):e60350. PubMed ID: 23565233
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.